Atyr Pharma Inc (ATYR)

$0.97 -0.01 (-0.74%)
Market Cap 95.32M
Revenue (ttm) 240,000.00
Net Income (ttm) -64.02M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -26,675.00%
Debt to Equity Ratio 0.00
Volume 2,788,200
Avg Vol 12,938,219
Day's Range N/A - N/A
Shares Out 97.99M
Stochastic %K 33%
Beta 0.79
Analysts Sell
Price Target $5.30

Company Profile

aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; and in Phase 1b/2a clinical trial to treat other interstitial lung diseases (ILDs), such as chronic hypersensitiv...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 731 8389
Fax: 858 731 8394
Address:
10240 Sorrento Valley Road, Suite 300, San Diego, United States
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 25 at 12:41 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $ATYR Current Share Price: $0.97 Contracts: $ATYR January 15, 2027 $1 Calls Scale in: $0.37- $0.45 Scale out: $0.58-$0.74 Can Easily Capture: 60% ROI Blended DTE: 447 Days | Join Elites here: https://liquidtheta.com
0 · Reply
GoodGollyGumboots
GoodGollyGumboots Oct. 24 at 7:01 PM
$ATYR if you've lost here today take a look at BURU...It's exploding now. 🚀
0 · Reply
__Godzilla__
__Godzilla__ Oct. 24 at 5:17 PM
$ATYR IMO, if aTyr were to issue a press release that they were engaging the FDA related to Efzofitimod, then the stock is fundamentally worth $ 5 based on the possibility, no matter how low, of approval based on the P3 data.
3 · Reply
Zackpedia
Zackpedia Oct. 24 at 3:28 PM
$ATYR Down to .94! hit Follow and subscribe to get my alerts on time and make money
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 23 at 10:25 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $ATYR Current Share Price: $0.97 Contracts: $ATYR January 15, 2027 $1 Calls Scale in: $0.41- $0.50 Scale out: $0.63-$0.81 Can Easily Capture: 60% ROI Blended DTE: 449 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
CaptainsLogs
CaptainsLogs Oct. 23 at 10:02 PM
$ATYR was there dilution here? Why the big drop?
0 · Reply
lifeonthewater
lifeonthewater Oct. 23 at 6:57 PM
$ATYR Only really good news will blast this thing Otherwise, go to sleep. I’ll wake you when it’s ready. 🤪
1 · Reply
Zackpedia
Zackpedia Oct. 23 at 6:29 PM
$ATYR Better not to buy it above 1
0 · Reply
Jmdouk2
Jmdouk2 Oct. 23 at 6:25 AM
$ATYR hey can someone send a sample to him. he sounds like he could use some. lets fast track this jr
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 23 at 12:57 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $ATYR Current Share Price: $0.97 Contracts: $ATYR January 15, 2027 $1 Calls Scale in: $0.42- $0.51 Scale out: $0.65-$0.83 Can Easily Capture: 60% ROI Blended DTE: 450 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
Latest News on ATYR
ATYR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma

Oct 23, 2025, 1:28 PM EDT - 2 days ago

ATYR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma

aTyr Pharma, Inc.'s (ATYR) Failed Drug Trial Spurs Securities Lawsuit -- Hagens Berman

Oct 22, 2025, 4:49 PM EDT - 3 days ago

aTyr Pharma, Inc.'s (ATYR) Failed Drug Trial Spurs Securities Lawsuit -- Hagens Berman

aTyr Pharma, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - ATYR

Oct 20, 2025, 3:26 AM EDT - 5 days ago

aTyr Pharma, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - ATYR

aTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FIT Study Failure Drives Shares 80% Lower -- Hagens Berman

Oct 9, 2025, 1:50 PM EDT - 16 days ago

aTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FIT Study Failure Drives Shares 80% Lower -- Hagens Berman

aTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FIT Study Failure Drives Shares 80% Lower – Hagens Berman

Oct 3, 2025, 2:32 PM EDT - 22 days ago

aTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FIT Study Failure Drives Shares 80% Lower – Hagens Berman

Ethos Technologies Targets IPO Amid Positive Insurance Offerings

Sep 30, 2025, 2:59 PM EDT - 25 days ago

Ethos Technologies Targets IPO Amid Positive Insurance Offerings

LIFE

aTyr Pharma Presents Additional Findings from Phase 3 EFZO-FIT™ Study in Late-Breaking Oral Abstract at the European Respiratory Society (ERS) Congress 2025

Sep 30, 2025, 5:30 AM EDT - 25 days ago

aTyr Pharma Presents Additional Findings from Phase 3 EFZO-FIT™ Study in Late-Breaking Oral Abstract at the European Respiratory Society (ERS) Congress 2025

Ethos Files Registration Statement for Proposed Initial Public Offering

Sep 26, 2025, 1:50 PM EDT - 4 weeks ago

Ethos Files Registration Statement for Proposed Initial Public Offering

LIFE

aTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FIT™ Study Failure Drives Shares 80% Lower -- Hagens Berman

Sep 23, 2025, 9:22 AM EDT - 4 weeks ago

aTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FIT™ Study Failure Drives Shares 80% Lower -- Hagens Berman

aTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FIT Study Failure Drives Shares 80% Lower -- Hagens Berman

Sep 22, 2025, 11:08 AM EDT - 4 weeks ago

aTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FIT Study Failure Drives Shares 80% Lower -- Hagens Berman

Top 3 Health Care Stocks That May Explode In September

Sep 19, 2025, 7:01 AM EDT - 5 weeks ago

Top 3 Health Care Stocks That May Explode In September

BSX RVPH

Foundation for Sarcoidosis Research Reacts to the Announcement of aTyr Pharma's Phase 3 Clinical Trial Results

Sep 17, 2025, 10:01 AM EDT - 5 weeks ago

Foundation for Sarcoidosis Research Reacts to the Announcement of aTyr Pharma's Phase 3 Clinical Trial Results

aTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FITÔ Study Failure Drives Shares 80% Lower -- Hagens Berman

Sep 17, 2025, 9:03 AM EDT - 5 weeks ago

aTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FITÔ Study Failure Drives Shares 80% Lower -- Hagens Berman

ATyr Pharma, Inc. (ATYR) Announces Top Line Results For The Phase III EFZO-FIT Study Of Efzofitimod In Pulmonary Sarcoidosis (Transcript)

Sep 15, 2025, 1:16 PM EDT - 5 weeks ago

ATyr Pharma, Inc. (ATYR) Announces Top Line Results For The Phase III EFZO-FIT Study Of Efzofitimod In Pulmonary Sarcoidosis (Transcript)

aTyr Pharma, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – ATYR

Sep 15, 2025, 12:06 PM EDT - 5 weeks ago

aTyr Pharma, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – ATYR

ATyr Pharma Stock Sinks, Plans FDA Review After Mixed Phase 3 Results

Sep 15, 2025, 11:24 AM EDT - 5 weeks ago

ATyr Pharma Stock Sinks, Plans FDA Review After Mixed Phase 3 Results

BREAKING: aTyr Pharma Shares Plummet 80%; Investors Should Contact Block & Leviton to Potentially Recover Losses

Sep 15, 2025, 10:57 AM EDT - 5 weeks ago

BREAKING: aTyr Pharma Shares Plummet 80%; Investors Should Contact Block & Leviton to Potentially Recover Losses

aTyr Pharma's lung disease drug misses main goal in late-stage trial

Sep 15, 2025, 7:55 AM EDT - 5 weeks ago

aTyr Pharma's lung disease drug misses main goal in late-stage trial

aTyr Pharma Announces Topline Results from Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis

Sep 15, 2025, 7:30 AM EDT - 5 weeks ago

aTyr Pharma Announces Topline Results from Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 5, 2025, 4:00 PM EDT - 7 weeks ago

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

aTyr Pharma Announces Second Quarter 2025 Results and Provides Corporate Update

Aug 7, 2025, 4:00 PM EDT - 2 months ago

aTyr Pharma Announces Second Quarter 2025 Results and Provides Corporate Update

Insurtech Leader Ethos Adds Industry Veteran William Wheeler to Board of Directors

Jul 30, 2025, 11:00 AM EDT - 3 months ago

Insurtech Leader Ethos Adds Industry Veteran William Wheeler to Board of Directors

LIFE

aTyr Pharma Announces Last Patient Visit in Phase 3 EFZO-FIT™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis

Jul 22, 2025, 8:00 AM EDT - 3 months ago

aTyr Pharma Announces Last Patient Visit in Phase 3 EFZO-FIT™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis

aTyr Pharma to be Added to the Russell 2000® and Russell 3000® Indexes

Jun 26, 2025, 8:00 AM EDT - 4 months ago

aTyr Pharma to be Added to the Russell 2000® and Russell 3000® Indexes

aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD)

Jun 4, 2025, 8:00 AM EDT - 5 months ago

aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD)

aTyr Pharma to Present at Upcoming Investor Conferences

May 20, 2025, 8:00 AM EDT - 5 months ago

aTyr Pharma to Present at Upcoming Investor Conferences

aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference

May 19, 2025, 8:00 AM EDT - 5 months ago

aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference

aTyr Pharma Advances ATYR0101 to IND Candidate Stage for Pulmonary Fibrosis

May 14, 2025, 8:00 AM EDT - 5 months ago

aTyr Pharma Advances ATYR0101 to IND Candidate Stage for Pulmonary Fibrosis

aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update

May 7, 2025, 4:01 PM EDT - 6 months ago

aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update

aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the American Association for Cancer Research (AACR) Annual Meeting 2025

Apr 29, 2025, 8:00 AM EDT - 6 months ago

aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the American Association for Cancer Research (AACR) Annual Meeting 2025

aTyr Pharma to Participate in April Investor Conferences

Apr 3, 2025, 8:00 AM EDT - 7 months ago

aTyr Pharma to Participate in April Investor Conferences

aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise

Mar 26, 2025, 8:00 AM EDT - 7 months ago

aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise

aTyr Pharma: Good Safety Data In Pulmonary Sarcoidosis, Institutions Are Accumulating

Mar 14, 2025, 3:10 PM EDT - 8 months ago

aTyr Pharma: Good Safety Data In Pulmonary Sarcoidosis, Institutions Are Accumulating

aTyr Pharma, Inc. (ATYR) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 11:18 PM EDT - 8 months ago

aTyr Pharma, Inc. (ATYR) Q4 2024 Earnings Call Transcript

aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update

Mar 13, 2025, 4:01 PM EDT - 8 months ago

aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update

aTyr Pharma Announces Publication Demonstrating Efzofitimod's Immunomodulatory Activity in Science Translational Medicine

Mar 12, 2025, 4:00 PM EDT - 8 months ago

aTyr Pharma Announces Publication Demonstrating Efzofitimod's Immunomodulatory Activity in Science Translational Medicine

aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis

Mar 6, 2025, 4:02 PM EST - 8 months ago

aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis

LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 25 at 12:41 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $ATYR Current Share Price: $0.97 Contracts: $ATYR January 15, 2027 $1 Calls Scale in: $0.37- $0.45 Scale out: $0.58-$0.74 Can Easily Capture: 60% ROI Blended DTE: 447 Days | Join Elites here: https://liquidtheta.com
0 · Reply
GoodGollyGumboots
GoodGollyGumboots Oct. 24 at 7:01 PM
$ATYR if you've lost here today take a look at BURU...It's exploding now. 🚀
0 · Reply
__Godzilla__
__Godzilla__ Oct. 24 at 5:17 PM
$ATYR IMO, if aTyr were to issue a press release that they were engaging the FDA related to Efzofitimod, then the stock is fundamentally worth $ 5 based on the possibility, no matter how low, of approval based on the P3 data.
3 · Reply
Zackpedia
Zackpedia Oct. 24 at 3:28 PM
$ATYR Down to .94! hit Follow and subscribe to get my alerts on time and make money
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 23 at 10:25 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $ATYR Current Share Price: $0.97 Contracts: $ATYR January 15, 2027 $1 Calls Scale in: $0.41- $0.50 Scale out: $0.63-$0.81 Can Easily Capture: 60% ROI Blended DTE: 449 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
CaptainsLogs
CaptainsLogs Oct. 23 at 10:02 PM
$ATYR was there dilution here? Why the big drop?
0 · Reply
lifeonthewater
lifeonthewater Oct. 23 at 6:57 PM
$ATYR Only really good news will blast this thing Otherwise, go to sleep. I’ll wake you when it’s ready. 🤪
1 · Reply
Zackpedia
Zackpedia Oct. 23 at 6:29 PM
$ATYR Better not to buy it above 1
0 · Reply
Jmdouk2
Jmdouk2 Oct. 23 at 6:25 AM
$ATYR hey can someone send a sample to him. he sounds like he could use some. lets fast track this jr
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 23 at 12:57 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $ATYR Current Share Price: $0.97 Contracts: $ATYR January 15, 2027 $1 Calls Scale in: $0.42- $0.51 Scale out: $0.65-$0.83 Can Easily Capture: 60% ROI Blended DTE: 450 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
Hallzzy55
Hallzzy55 Oct. 22 at 5:36 PM
$ATYR what’s everyone’s price target ?
4 · Reply
OnlyBuyMoreShareSqueezes
OnlyBuyMoreShareSqueezes Oct. 22 at 4:58 PM
$ATYR ignore the bot noise , facts are that it’s is over 40% shorted as of total float , that means that 4 shares for every 10 that exist has a duplicate share in someones account , squeeze is likely , someone who owes these shares will try and make it difficult to squeeze , STAY THE COURSE , buy the ask , remove shares from circulation and this will squeeze !
0 · Reply
cubie
cubie Oct. 22 at 2:45 PM
$ARCT @judgeyoung2 for spec bios, whales smarter than retail. They always know. Thats how cubie new $ATYR would tank last month. Nothing but poots. Cubie teaches
1 · Reply
Yeueehehe
Yeueehehe Oct. 22 at 1:57 PM
$ATYR wow huge selling wtf
2 · Reply
StockArbitrage
StockArbitrage Oct. 22 at 1:10 PM
$ARCT $5 when market opens? It’s looking like a $ATYR bloodbath
0 · Reply
jbjhh
jbjhh Oct. 22 at 12:23 PM
$ATYR 🤔
0 · Reply
Unknown_Stuntman
Unknown_Stuntman Oct. 22 at 12:00 PM
$ATYR even $SAVA managed to double in a month from its P3 failure price, but of course since I own THIS stock, it goes nowhere.
0 · Reply
XX900
XX900 Oct. 22 at 10:34 AM
$ATYR Let's starting the day with strong motivation
0 · Reply
XX900
XX900 Oct. 21 at 10:30 PM
$ATYR Nice to be back again, some some spam my account.
0 · Reply
E_Drop
E_Drop Oct. 21 at 5:13 PM
$ATYR $BYND ...
0 · Reply
OnlyBuyMoreShareSqueezes
OnlyBuyMoreShareSqueezes Oct. 21 at 4:59 PM
$ATYR $ATER I’m tagging both because I don’t feel like making two posts for the same comment lol I was going to say , let’s get some big green long term candles!! The sooner we get to 6+ the better , but the longer it takes the more I will have ! So both is good for me long term
0 · Reply
Yeueehehe
Yeueehehe Oct. 21 at 4:13 PM
$ATYR dead stock
1 · Reply